What Is KPV?
KPV (Lys-Pro-Val) is a C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (alpha-MSH). It consists of just three amino acids — lysine, proline, and valine — making it one of the smallest peptides studied for therapeutic applications.
Alpha-MSH is a naturally occurring neuropeptide involved in inflammation regulation, pigmentation, and immune modulation. KPV retains the anti-inflammatory activity of its parent molecule without the melanogenic (tanning) effects, making it a cleaner candidate for inflammatory conditions.
Quick Facts
| Property | Detail |
|---|---|
| Full Name | Lysine-Proline-Valine (Lys-Pro-Val) |
| Type | Tripeptide fragment of alpha-MSH |
| Molecular Weight | ~312 Da |
| Mechanism | Melanocortin receptor binding; NF-κB pathway inhibition |
| Key Target | Inflammatory cytokine reduction |
| Regulatory Status | Category 2 → reclassification expected |
Mechanism: How KPV Works
KPV exerts its anti-inflammatory effects through two complementary pathways:
- Melanocortin receptor binding — KPV binds melanocortin receptors (particularly MC1R and MC3R), which are expressed on immune cells, gut epithelium, and skin. Receptor activation initiates anti-inflammatory signaling cascades.
- NF-κB pathway inhibition — KPV downregulates nuclear factor kappa B (NF-κB), a master regulator of inflammatory gene expression. By suppressing NF-κB activity, KPV reduces production of pro-inflammatory cytokines including:
- TNF-α (tumor necrosis factor-alpha)
- IL-6 (interleukin-6)
- IL-1β (interleukin-1 beta)
This dual mechanism — receptor-mediated and intracellular — distinguishes KPV from simpler anti-inflammatory peptides.
Research Areas of Interest
- Inflammatory bowel disease (IBD) — KPV has been studied in preclinical models of Crohn's disease and ulcerative colitis, where it reduced mucosal inflammation and promoted gut barrier integrity
- Gut permeability — research suggests KPV may help restore tight junction integrity in inflamed intestinal epithelium, reducing "leaky gut" pathology
- Wound healing — anti-inflammatory activity and melanocortin receptor signaling may support tissue repair in chronic wound environments
- Skin inflammation — topical KPV has been studied for conditions involving cutaneous inflammation, leveraging its activity at skin-resident melanocortin receptors
Forms Available Through Compounding
Because KPV is a small, stable tripeptide, it is well-suited to multiple delivery routes through compounding pharmacies:
| Form | Route | Primary Application |
|---|---|---|
| Oral capsule | Oral | IBD, gut inflammation, systemic use |
| Topical cream/gel | Topical | Skin inflammation, wound healing |
| Injectable solution | Subcutaneous | Systemic anti-inflammatory use |
The oral and topical routes are particularly notable: small peptides like KPV can survive partial GI transit and penetrate skin barriers more readily than larger peptides, making non-injectable formulations viable for many applications.
Regulatory Status
KPV is currently classified as Category 2 under FDA rulemaking and cannot be legally compounded or prescribed in the United States at this time.
KPV is one of the 14 peptides expected to be reclassified to Category 1 through the 2026 FDA process, which would restore legal compounding access through licensed 503A and 503B pharmacies.
How Valitide Will Offer KPV
Once the FDA reclassification is finalized, Valitide will offer KPV through licensed telehealth providers and vetted 503A/503B compounding pharmacies. Given KPV's flexibility across delivery routes, prescriptions may be written for oral, topical, or injectable formulations depending on the patient's clinical needs and provider judgment.
All prescriptions will require evaluation by a licensed physician or nurse practitioner and dispensing from a licensed compounding pharmacy meeting applicable USP standards.
Join the waitlist to be notified when prescription access becomes available.